Buy Into the Strength of CVS As the Vaccines Roll Out

Tuesday, February 16, 2021 | Chris Markoch
Buy Into the Strength of CVS As the Vaccines Roll Out

Shares of CVS (NYSE: CVS) stock are sharply down in early trading after the pharmacy chain released its fourth-quarter earnings. The nation’s largest pharmacy health care provider posted earnings per share (EPS) of $1.30, beating analysts’ estimates by six cents. Revenue came in at $69.28 which was a 4% year-over-year (YOY) gain.

Lynch advised for 2021 adjusted earnings to come in between $7.39 and $7.55 per share. Some analysts are forecasting at the high end of that range.

So why are the shares falling? It seems like a case of investors expecting more from the pharmacy chain. And this was the first earnings call with the company’s new CEO Karen Lynch.

CVS stock was up nearly 6% for the year prior to the earnings report. But it was off of its 52-week high set in early January, and was up less than 1% in the last 12 months.

Covid-19 Was Not a Huge Revenue Boost

CVS is one of many pharmacy chains that are receiving doses of the Covid-19 vaccine. The pharmacy chain is delivering the vaccines in its pharmacies by appointment.

However, CVS is also playing a key role in ensuring the vaccine is distributed in long-term care facilities. This is a key strategic initiative to beating the pandemic. To that end, the company said it has administered over 3 million vaccines in approximately 40,000 long-term care facilities, although the company acknowledged this had little bearing on overall results.

And the brick-and-mortar locations continue to serve as Covid-19 testing sites. The company says it has administered 15 million coronavirus tests to date.

In the earnings report, the company says it projects approximately $400,000 to $500,000 in 2021 revenue to come from Covid-19 related activities.

Focus on Wellness

That means there has to be another catalyst. And, according to the company’s new CEO Karen Lynch, that appears to be retail sales. In the fourth quarter, CVS saw retail sales increase by 7% from the same quarter in 2019. Lynch expressed confidence for similar gains in 2021.

Based on the reaction of investors they are skeptical that this will happen.  The growth of e-commerce has affected pharmacy chains due to a decline in front-of-the-store sales. That was amplified by the pandemic as people were afraid to leave their home, particularly those in the most vulnerable population that make up a good percentage of the company’s customer base.

But if the company is successful at bringing individuals into its stores to get the vaccine, it gives them an opportunity to stay top of mind. This is important because the entire industry is mindful of the potential threat posed by Amazon (NASDAQ:AMZN). However, through 2019, CVS led the industry in market share which gives it a little bit of breathing room to expand its other services.

And right now, the stores acknowledge that growth needs to come from giving pharmacy customers a compelling reason to come in the store. For CVS, that reason appears to be on wellness.

According to Lynch, the company’s goal “is to make health care more accessible, more affordable and simpler.” The practical response from CVS came shortly before the pandemic when it began opening HealthHUB stores.

The HealthHUB is a store-in-store concept. Except in this case, the other store is manned by medical professionals who give the company the ability to offer expanded health care services and offerings. The pandemic slowed this expansion. However, the company plans to expand this concept to 1,500 locations by the end of this year.

Analysts like CVS Stock

One reason the bulls can cheer is that analysts like the stock. Of 15 analysts that are offering opinions, the company has 12 buy ratings and 3 hold ratings. Plus, the consensus 12-month price target stands at $82.08 which would be a gain of over 13% from its present level.

Buy CVS On its Underlying Strength

CVS is not a vaccine play. The company should be applauded for doing its part, but the numbers don’t suggest this will have a large effect on its bottom line. Where the company has a chance to shine is in its role as a bridge between a primary care physician and the patient.

Admittedly, investors may be waiting for CVS to prove it, but with a price target that suggests a 13% upside, CVS stock looks like a winner as traffic should continue to return to normal levels.

Featured Article: G-20



7 Semiconductor Stocks Set to Gain From the Chip Shortage

Who knew that something so tiny could create such a big problem? However, that’s the case with the semiconductor industry. Chip manufacturers are facing supply chain disruptions due to the Covid-19 pandemic.

Semiconductors are in high demand for the big tech companies who need the chips to power the servers for their data centers. But they are also needed for much of the technology we take for granted including laptops, tablets, mobile phones, gaming consoles, and automobiles – a sector that seems to be at the root of the current crisis.

Any weekend mechanic knows that even traditional internal combustion cars are heavily reliant on electronics. In fact, electronic parts and components account for 40% of a new, internal combustion vehicle. That’s more than doubled since 2000.

However as it turns out, some manufacturers may have overestimated how soon consumers would be ready for an “all-electric” future. And that meant that they didn’t forecast how much demand there would be for the kind of chips needed to do the mundane, but vital tasks of steering, braking, and even powering windows up and down.

Part of the problem is that U.S. businesses are heavily reliant on countries like China and Taiwan for their semiconductors. In fact, only about 12.5% of semiconductor manufacturing is done in the United States.

Of course, this creates a tremendous opportunity for the companies that manufacture these chips. And it comes at a good time. The semiconductor sector is notoriously cyclical and was coming down from the elevated demand for the 5G buildout.

In this special presentation, we’ll give you a list of seven semiconductor companies that you can invest in to take advantage of this opportunity.

View the "7 Semiconductor Stocks Set to Gain From the Chip Shortage".


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
CVS Health (CVS)2.3$76.14-0.7%2.63%12.59Buy$84.31
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.